Vaccine News and Research

Latest Vaccine News and Research

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

In Austin, some try to address vaccine inequity, but a broad plan is elusive

Communities of color have been among the hardest hit during the pandemic. But advocates in Texas say those communities are likely to have a harder time getting the vaccine in the coming months, so they are urging local leaders to step in.

3 Feb 2021

100 million covid shots in 100 days doesn’t get us back to normal

April 30 will mark the end of the first 100 days of President Joe Biden's tenure. That's a benchmark presidents often set for making good on high-priority campaign promises.

3 Feb 2021

Researchers survey repurposed drugs that inhibit SARS-CoV-2 replication in vitro

A new study by researchers at the University of Manchester, UK, reports on the compounds of interest that were identified as having potential for the treatment of COVID-19, from a library of almost 2,000 compounds from the APExBIO DiscoveryProbe library.

3 Feb 2021

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

A new preprint examines Long COVID-19, aiming to identify the underlying immunologic status in such patients.

3 Feb 2021

Study finds higher pediatric SARS-CoV-2 burden than previously reported in the U.S.

In a new study, published on the pre-print server medRxiv*, researchers at Inova Children's Hospital and the George Mason University revealed that a much higher burden of SARS-CoV-2 infection was found in children than previously reported. This comes after the researchers assessed seropositivity among 1,038 children and adolescents.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection

The findings reveal that healthcare workers previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop significantly higher antibody titers in response to a single dose of COVID-19 vaccine, as compared to healthcare workers without prior SARS-CoV-s infection. The study is currently available on the medRxiv* preprint server.

2 Feb 2021

Lysosomal-immune axis associated with COVID-19 severity

New research suggests the modulation of lysosomal-immune pathways may present a novel drug-targeting strategy to attenuate SARS-CoV-2 infections.

2 Feb 2021

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Researchers in the United States have shown that two doses of vaccine may not be necessary to protect against coronavirus disease 2019 (COVID-19) among people who have already been infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Feb 2021

Pfizer-BioNTech vaccine shows promise against new SARS-CoV-2 variants

A team of researchers in the U.S. studied the Pfizer-BioNTech vaccine candidate - currently being rolled out in many parts of the world to high-risk individuals - to see if it still holds up against mutant strains of the virus and yielded encouraging results.

2 Feb 2021

Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Why SARS-CoV-2 B.1.1.7 is more virulent

A new preprint research paper by scientists from Sweden and India attempts to provide a preliminary answer to these questions using computational modeling. The research, which appears on the bioRxiv* server, predicts increased virulence with the new variant. If validated, this could help public health authorities prepare for new variants' possible impact as they emerge.

2 Feb 2021

New protein acts as trickster to neutralize COVID-19 infection in human kidney organoid

Decoy protein intercepts spike of coronavirus. Virus prevented from infecting human cells. Protein may be a new way to treat and prevent COVID-19.

1 Feb 2021

By July of 2020, 16.8 million people in the US infected with SARS-CoV-2 and didn’t know it

A seroprevalence study of nearly 10,000 people in the United States in the first six months of the COVID-19 pandemic suggests there were at least five people with undiagnosed disease for every case diagnosed.

1 Feb 2021